Defective domain-domain interactions within the ryanodine receptor as a critical cause of diastolic Ca2+ leak in failing hearts

Cardiovascular Research

Volumn 81, Issue 3, 2009, Pages 536-545

  Tateishi, Hiroki ^a   Yano, Masafumi ^a   Mochizuki, Mamoru ^a   Suetomi, Takeshi ^a   Ono, Makoto ^a   Xu, Xiaojuan ^a   Uchinoumi, Hitoshi ^a   Okuda, Shinichi ^a   Oda, Tetsuro ^a   Kobayashi, Shigeki ^a   Yamamoto, Takeshi ^a   Ikeda, Yasuhiro ^a   Ohkusa, Tomoko ^a   Ikemoto, Noriaki ^b,c   Matsuzaki, Masunori ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b BOSTON BIOMEDICAL RESEARCH INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Calcium (cellular); Heart failure; Ion channels; SR (function)

Indexed keywords

ACETIC ACID DERIVATIVE; CALCIUM ION; METHYLCOUMARIN ACETATE; RYANODINE RECEPTOR; RYANODINE RECEPTOR 2; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL VACUOLE; CONTROLLED STUDY; DIASTOLE; DOG; FLUORESCENCE; HEART ARRHYTHMIA; HEART FAILURE; HEART MUSCLE CELL; HEART VENTRICLE WALL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN INTERACTION; SARCOPLASMIC RETICULUM;

ANIMALS; ARRHYTHMIAS, CARDIAC; BINDING SITES; CALCIUM; CALCIUM SIGNALING; CARDIAC PACING, ARTIFICIAL; DISEASE MODELS, ANIMAL; DOGS; FLUORESCENT DYES; HEART FAILURE; HEART VENTRICLES; MICROSCOPY, CONFOCAL; MYOCYTES, CARDIAC; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN INTERACTION MAPPING; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SARCOPLASMIC RETICULUM; SPECTROMETRY, FLUORESCENCE; TACROLIMUS BINDING PROTEINS; TIME FACTORS;

EID: 59449088323     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvn303     Document Type: Article

References (26)

1. Yano M, Yamamoto T, Ikemoto N, Matsuzaki M. Abnormal Ryanodine Receptor Function in Heart Failure. (Review). Pharmacol Therapeut 2005;107:377-391.
2. Wehrens XH, Lehnart SE, Huang F, Vest JA, Reiken SR, Mohler PJ et al. FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death. Cell 2003;113:829-840.
3. Marx SO, Reiken S, Hisamatsu Y, Jayaraman T, Burkhoff D, Rosemblit N et al. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): Defective regulation in failing hearts. Cell 2000;101:365-376.
4. 2+ release, but normal ryanodine receptors, in canine and human heart failure. Circ Res 2002;91:1015-1022.
5. 2+-release channel (ryanodine receptor) does not dissociate 12.6-kDa FK506-binding protein (FKBP12.6). Circ Res 2004;94:487-495.
6. Priori SG, Napolitano C, Tiso N, Memmi M, Vignati G, Bloise R et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation 2001;103:196-200.
7. Laitinen PJ, Brown KM, Piippo K, Swan H, Devaney JM, Brahmbhatt B et al. Mutations of the cardiac ryanodine receptor (RyR2) gene in familial polymorphic ventricular tachycardia. Circulation 2001;103:485-490.
8. Tiso N, Stephan DA, Nava A, Bagattin A, Devaney JM, Stanchi F et al. Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2). Hum Mol Genet 2001;10:189-194.
9. Oda T, Yano M, Yamamoto T, Tokuhisa T, Okuda S, Doi M et al. Defective regulation of inter-domain interactions within the ryanodine receptor plays a key role in the pathogenesis of heart failure. Circulation 2005;111:3244-3254.
10. Liu N, Colombi B, Memmi M, Zissimopoulos S, Rizzi N, Negri S et al. Arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia: insights from a RyR2 R4496C knock-in mouse model. Circ Res 2006;99:292-298.
11. George CH, Jundi H, Thomas NL, Scoote M, Walters N, Williams AJ et al. Ryanodine receptor regulation by intramolecular interaction between cytoplasmic and transmembrane domains. Mol Biol Cell 2004;15:2627- 2638.
12. 2+ leak through ryanodine receptor in heart failure. Circulation 2000;102:2131-2136.
13. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-275.
14. Yamamoto T, Ikemoto N. Peptide probe study of the critical regulatory domain of the cardiac ryanodine receptor. Biochem Biophys Res Commun 2002;291:1102-1108.
15. Yamamoto T, Ikemoto N. Spectroscopic monitoring of local conformational changes during the intramolecular domain-domain interaction of the ryanodine receptor. Biochemistry 2002;41:1492-1501.
16. 2+) channel regulation. J Biol Chem 2000;275:11618-11625.
17. Igarashi-Saito K, Tsutsui H, Yamamoto S, Takahashi M, Kinugawa S, Tagawa H et al. Role of SR Ca -ATPase in contractile dysfunction of myocytes in tachycardia-induced heart failure. Am J Physiol 1998;274:H31-H40.
18. Terentyev D, Nori A, Santoro M, Viatchenko-Karpinski S, Kubalova Z, Gyorke I et al. Abnormal interactions of calsequestrin with the ryanodine receptor calcium release channel complex linked to exercise-induced sudden cardiac death. Circ Res 2006;98:1151-1158.
19. Picht E, Zima AV, Blatter LA, Bers DM. SparkMaster - automated calcium spark analysis with ImageJ. Am J Physiol Cell Physiol 2007;293:C1073-C1081.
20. 2+ release channel dysfunction. Circ Res 2006;98:88-97.
21. 2+-binding domain in RyR1 that interacts with the calmodulin binding site and modulates channel activity. Biophys J 2006;90:173-182.
22. Yano M, Okuda S, Oda T, Tokuhisa T, Tateishi H, Mochizuki M et al. Correction of defective interdomain interaction within ryanodine receptor by antioxidant is a new therapeutic strategy against heart failure. Circulation 2005;112:3633-3643.
23. Yamamoto T, Yano M, Xu X, Uchinoumi H, Tateishi H, Mochizuki M et al. Identification of target domains of the cardiac ryanodine receptor to correct channel disorder in failing hearts. Circulation 2008;117:762-772.
24. Bers DM. Sarcoplasmic reticulum Ca release in intact ventricular myocytes. Front Biosci 2002;7:d1697-d1711.
25. 2+ release (SOICR). Proc Natl Acad Sci USA 2004;101:13062-13067.
26. 2+ activation are common defects of RyR2 mutations linked to ventricular tachycardia and sudden death. Circ Res 2005;97:1173-1181.